Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma
NCT ID: NCT01202448
Last Updated: 2015-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
600 participants
INTERVENTIONAL
2010-08-31
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
NCT02474550
The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study
NCT05169203
Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region
NCT04859920
Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma
NCT01448096
The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)
NCT01266668
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DLBCL with risk factor
Patients have any of risk factors for secondary CNS involvement
CSF analysis
The cerebrospinal fluid will be evaluated via lumbar puncture.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CSF analysis
The cerebrospinal fluid will be evaluated via lumbar puncture.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. \> 20 years
3. life expectancy more than 6 months
4. Written informed consent
Exclusion Criteria
2. Lymphomas other than diffuse large B cell lymphoma
3. Primary CNS lymphoma
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asan Medical Center
OTHER
Yonsei University
OTHER
National Cancer Center, Korea
OTHER_GOV
Korea Cancer Center Hospital
OTHER
Korea University
OTHER
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kim, Seok Jin
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cheolwon Suh, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Consortium for Improving Survival of Lymphoma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-04-091
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.